Clinical Trials Browser

Diabetes Mellitus, Carcinoma, Hepatocellular

Esophageal Neoplasms

Carcinoma, Non-Small-Cell Lung

Unresectable Stage III Non-small Cell Lung Cancer

Esophageal Squamous Cell Carcinoma

Colorectal Neoplasms

Small Cell Lung Carcinoma

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Recurrence, Lymphoma, Extranodal NK-T-Cell

Small Cell Lung Carcinoma

Carcinoma, Hepatocellular

Locally Advanced Rectal Cancer

Carcinoma, Non-Small-Cell Lung

Advanced Solid Tumor

Nasopharyngeal Carcinoma

Adenocarcinoma

Non Squamous Non-small Cell Lung Cancer

Nasopharyngeal Neoplasms

Carcinoma, Hepatocellular

Tongue Squamous Cell Carcinoma

Neoplasm Metastasis

Nasopharyngeal Carcinoma

Gastric Cancer Peritoneal Metastases

Extensive Stage Lung Small Cell Cancer

Digestive System Neoplasms

Colonic Neoplasms

Esophageal Squamous Cell Carcinoma

Urinary Bladder Neoplasms, Neoplasms

Colorectal Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Esophageal Neoplasms

Esophageal Squamous Cell Carcinoma

Gastric Cancer Stage

Carcinoma, Non-Small-Cell Lung

Lymphoma, Follicular

Esophageal Neoplasms

Esophageal Neoplasms

Small Cell Lung Carcinoma

Esophageal Neoplasms, Stomach Neoplasms

Biliary Tract Neoplasms, Cholangiocarcinoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Stomach Neoplasms

Esophageal Neoplasms

Urinary Bladder Neoplasms

SCLC, Extensive Stage

Nasopharyngeal Carcinoma

Clinical Trials

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes

MRD2START

Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC

BEACON-Lung

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

TRIUNITE06

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)

A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma

Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin

KontRASt-R

EpiRev-NKT

A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

FMT-LUNG

Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus

Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer

ATARI-PDAC

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer

WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy

Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer

A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC

A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL

Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma

The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

TisGCS for BTC

An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer

Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia

A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma